China NMPA Product Recall - Femoral Stem

Zimmer Inc., through its subsidiary Zimmer (Shanghai) Medical International Trading Co., Ltd., has initiated a voluntary Class II recall of specific models and batches of its femoral stem cells. This action was officially announced by the National Medical Products Administration (NMPA) on August 4, 2023, under index number JGXX-2023-10146. The primary reason for the recall is the discovery of incorrect labeling on the affected products. These femoral stem cells are critical medical devices, registered in China under National Medical Device Registration No. 20173130148. A Class II recall designation signifies that the product defect, in this case, incorrect labeling, could potentially lead to temporary or medically reversible adverse health consequences. While the probability of serious adverse health consequences is considered remote, accurate labeling is paramount in the medical device industry to ensure proper product identification, usage, and patient safety. Zimmer's proactive recall aims to rectify this critical issue, demonstrating the company's commitment to upholding product quality and adhering to regulatory standards set by the NMPA. Manufacturers are obligated under the regulatory framework to ensure all medical devices are correctly labeled, providing essential information for healthcare professionals and patients. Further specifics regarding the exact models, specifications, and batch numbers impacted by this recall are detailed in the accompanying "Medical Device Recall Event Report Form." This incident highlights the continuous need for rigorous quality control throughout the manufacturing and distribution process of medical devices.